Skip to main content
Premium Trial:

Request an Annual Quote

Swift Bio, Fluxion Develop Liquid Biopsy Workflow

NEW YORK (GenomeWeb) – Swift Biosciences and Fluxion Biosciences have teamed up to develop a clinical oncology research workflow designed to detect somatic mutations from patient blood samples.

The jointly developed workflow uses Fluxion's IsoFlux system for circulating tumor cell enrichment along with Swift's Accel-Amplicon technology.

IsoFlux enriches rare tumor cells circulating in the blood using a combination of epithelial and mesenchymal markers, and delivers them at high purity for molecular analysis.

Meantime, Swift's Accel-Amplicon 56G Oncology Panel combines target enrichment, library preparation, and sequencing on Illumina platforms to provide sensitive mutation detection across 56 cancer-related genes using very low starting DNA inputs from the IsoFlux System.

The workflow and associated products are for research use only, the companies noted.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.